AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2037418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenol treatment)
Number of subjects: 46
Study 7016224 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy alone
Number of subjects: 77
Study 7016224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy plus living BCG vaccinations
Number of subjects: 77
Study 30475753 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 34
Study 30475753 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 34
Study 28115667 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of zinc
Number of subjects: 2500
Study 28115667 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 IU of vitamin A
Number of subjects: 2500
Study 28115667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2,500 IU of vitamin A and 25 mg of zinc
Number of subjects: 2500
Study 28115667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 25887759 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) with a decision support tool and 2-hour training for GPs
Number of subjects: 150
Study 25887759 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing with the treatment allocated in the ADDITION study
Number of subjects: 150
Study 24225157 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX plus bevacizumab
Number of subjects: 512
Study 24225157 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 512
Study 21884578 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 226
Study 21884578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 226
Study 21884578 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 226
Study 21884578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 226
Study 21884578 — intervention group
Group type: EXPERIMENTAL
Intervention: All SGAs (Olanzapine, Quetiapine, Risperidone, Ziprasidone)
Number of subjects: 226
Study 19595568 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 190
Study 19595568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study 15972619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg injections every 3 weeks
Number of subjects: 65
Study 12812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy (SRT) boost to 20 Gy in four fractions following partial brain irradiation to a dose of 60 Gy in 30 fractions
Number of subjects: 17
Study 12812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy (SRT) boost to 10 Gy (2 patients)
Number of subjects: 17
Study 10319907 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day plus cyproheptadine 24 mg/day
Number of subjects: 30
Study 10319907 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 30 mg/day plus placebo
Number of subjects: 30
Study 8532270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg, three times per day from 36 weeks' gestation until delivery
Number of subjects: 46
Study 8532270 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three times per day from 36 weeks' gestation until delivery
Number of subjects: 46
Study 8532270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg
Number of subjects: 46
Study 8532270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 1747891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified prevention program (Group 2)
Number of subjects: 323
Study 1747891 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preventive care (Group 1)
Number of subjects: 323
Study 1747891 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (Group 3)
Number of subjects: 323
Study 6356974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam
Number of subjects: 0
Study 6356974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31112373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 4175
Study 31112373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 4175
Study 28402351 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of deproteinized bovine bone mineral (DBBM; Endobon) covered with a soft tissue punch from the palate (Tx1)
Number of subjects: 35
Study 28402351 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of DBBM without soft tissue punch (Tx2)
Number of subjects: 35
Study 28402351 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of an adsorbable collagen membrane (Osseoguard) covering the DBBM (Tx3)
Number of subjects: 35
Study 28402351 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 35
Study 26304905 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 26304905 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 120
Study 26304905 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GP)
Number of subjects: 120
Study 26304905 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills (PP)
Number of subjects: 120
Study 23701770 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (Group 1), starting feeds 24h post-operation with a protocol driven increase
Number of subjects: 31
Study 23701770 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2), managed without a specific protocol
Number of subjects: 31
Study 21143248 — intervention group
Group type: EXPERIMENTAL
Intervention: L-cysteine (200 mg)
Number of subjects: 7
Study 21143248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 19321405 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied gentamicin
Number of subjects: 202
Study 19321405 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gentamicin
Number of subjects: 202
Study 17156222 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg administered intravenously 30 min before the end of surgery
Number of subjects: 90
Study 17156222 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg administered intravenously 30 min before the end of surgery
Number of subjects: 90
Study 17156222 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90
Study 17156222 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 90
Study 17156222 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Ondansetron
Number of subjects: 90
Study 15996249 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum creatinine
Number of subjects: 1052
Study 15996249 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft loss
Number of subjects: 1052
Study 12441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 80% of maximal voluntary concentric strength (n = 45)
Number of subjects: 42
Study 12441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 100% of maximal voluntary concentric strength (n = 36)
Number of subjects: 42
Study 12441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 120% of maximal voluntary concentric strength (n = 30)
Number of subjects: 42
Study 12441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting blood pressure measurements averaged over 6 days
Number of subjects: 42
Study 12441833 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain intensity ratings between sexes
Number of subjects: 42
Study 10501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antioxidants, niacin, and warfarin
Number of subjects: 468
Study 10501408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 10501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Active niacin group
Number of subjects: 468
Study 10501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 468
Study 8604625 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarction
Number of subjects: 45
Study 8604625 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-wave infarction
Number of subjects: 45
Study 8604625 — intervention group
Group type: COMPARATOR
Intervention: Control patients without recent infarction
Number of subjects: 45
Study 8604625 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak creatine phosphokinase levels
Number of subjects: 45
Study 8604625 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in left ventricular end-diastolic index
Number of subjects: 45
Study 1681430 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (up to 1,200 mg daily) with 100 mg pyridoxine for four weeks
Number of subjects: 15
Study 1681430 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 6125276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine treated group
Number of subjects: 220
Study 6125276 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 220
Study 6125276 — intervention group
Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 220
Study 6125276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 220
Study 30328031 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin once a day
Number of subjects: 50
Study 30033435 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically tailored breast cancer education program
Number of subjects: 209
Study 30033435 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study 27588701 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50mg
Number of subjects: 0
Study 27588701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24439959 — intervention group
Group type: EXPERIMENTAL
Intervention: Right‐sided rTMS to VLPFC
Number of subjects: 17
Study 24439959 — intervention group
Group type: EXPERIMENTAL
Intervention: Right‐sided rTMS to TPJ
Number of subjects: 17
Study 24439959 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving rTMS)
Number of subjects: 17
Study 22207227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 310
Study 22207227 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 310
Study 20976430 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program 'Pro Kind' (treatment group)
Number of subjects: 755
Study 20976430 — intervention group
Group type: COMPARATOR
Intervention: Standard community service (control group)
Number of subjects: 755
Study 17517002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood intervention (Abecedarian study)
Number of subjects: 104
Study 17517002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early childhood intervention)
Number of subjects: 104
Study 17517002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood intervention
Number of subjects: 104
Study 16366815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 20
Study 16366815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 20
Study 16366815 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum (0 mg)
Number of subjects: 20
Study 12068793 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP (cyclophosphamide 1000mg m(‐2), vincristine 2mg, epirubicin 70mg m(‐2) on day 1, prednisone 60mg on days 1‐7)
Number of subjects: 249
Study 12068793 — intervention group
Group type: COMPARATOR
Intervention: CNOP (cyclophosphamide 1000mg m(‐2), vincristine 2mg, mitoxantrone 12mg m(‐2) on day 1, prednisone 60mg on days 1‐7)
Number of subjects: 249
Study 12068793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEOP and CNOP
Number of subjects: 249
Study 9851759 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (300 mg, im, every 3 weeks for 6 months)
Number of subjects: 51
Study 9851759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9851759 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 51
Study 7879301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fat
Number of subjects: 0
Study 2212203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripton/Occlusin
Number of subjects: 50
Study 2212203 — intervention group
Group type: EXPERIMENTAL
Intervention: XR Bond/Herculite XR
Number of subjects: 50
Study 2212203 — intervention group
Group type: COMPARATOR
Intervention: Gluma/Lumifor
Number of subjects: 50
Study 2212203 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond 2/P50
Number of subjects: 50
Study 2212203 — intervention group
Group type: COMPARATOR
Intervention: Superbond C & B/Occlusin
Number of subjects: 50
Study 105099 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 65
Study 105099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 105099 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (after switching from placebo)
Number of subjects: 65
Study 29278555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (RM-group, n=21)
Number of subjects: 42
Study 29278555 — intervention group
Group type: COMPARATOR
Intervention: Standard protective ventilation (C-group, n=21)
Number of subjects: 42
Study 26869247 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/2 mg buprenorphine/samidorphan
Number of subjects: 0
Study 26869247 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/8 mg buprenorphine/samidorphan
Number of subjects: 0
Study 26869247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24980134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet containing pistachios (20% of total energy) for 4 weeks
Number of subjects: 30
Study 24980134 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (27% fat) for 4 weeks
Number of subjects: 30
Study 22302908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (oral dose before surgery)
Number of subjects: 0
Study 22302908 — intervention group
Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 0
Study 20721445 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct immunofluorescence assay (DFA)
Number of subjects: 291
Study 20721445 — intervention group
Group type: COMPARATOR
Intervention: Real-time polymerase chain reaction (RT-PCR)
Number of subjects: 291
Study 18237866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (P)
Number of subjects: 80
Study 18237866 — intervention group
Group type: COMPARATOR
Intervention: Swallowed fluticasone (F)
Number of subjects: 80
Study 15936062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (10 mg)
Number of subjects: 8
Study 15936062 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 8
Study 15936062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Methamphetamine (10 mg) and Zolpidem (10 mg)
Number of subjects: 8
Study 15936062 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both Methamphetamine and Zolpidem
Number of subjects: 8
Study 12955029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 0
Study 12955029 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary dissection
Number of subjects: 0
Study 10543415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg medrogestone (Prothil)
Number of subjects: 23
Study 10543415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 23
Study 8905423 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin stimulation test during septic shock
Number of subjects: 20
Study 8905423 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin stimulation test after recovery
Number of subjects: 20
Study 8905423 — intervention group
Group type: COMPARATOR
Intervention: Comparison of APACHE II scores
Number of subjects: 20
Study 1907740 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH i.v. (200 micrograms)
Number of subjects: 22
Study 1907740 — intervention group
Group type: EXPERIMENTAL
Intervention: Human CRH and ovine CRH (100-200 micrograms i.v.)
Number of subjects: 22
Study 1907740 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH
Number of subjects: 22
Study 6352020 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly high‐dose asparaginase
Number of subjects: 72
Study 6352020 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (vincristine, prednisone, doxorubicin)
Number of subjects: 72
Study 31319653 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bilirubin levels (measured using genetic variants)
Number of subjects: 33598
Study 31319653 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs12993249 (USP40)
Number of subjects: 33598
Study 29743330 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity education and communication skills intervention
Number of subjects: 1600
Study 29743330 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity education-only intervention
Number of subjects: 1600
Study 27049778 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy (LC)
Number of subjects: 30
Study 27049778 — intervention group
Group type: COMPARATOR
Intervention: Active Nonoperative Therapy (NO) with low-dose neuromodulator (amitriptyline 25 mg/day)
Number of subjects: 30
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 214
Study 24867013 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 214
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy
Number of subjects: 214
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary sphincterotomy
Number of subjects: 214
Study 24867013 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 214
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary sphincterotomy (observational study)
Number of subjects: 214
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy (observational study)
Number of subjects: 214
Study 24867013 — intervention group
Group type: EXPERIMENTAL
Intervention: No sphincterotomy (observational study)
Number of subjects: 214
Study 22240564 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated online support group
Number of subjects: 50
Study 22240564 — intervention group
Group type: COMPARATOR
Intervention: Peer-led online support group
Number of subjects: 50
Study 20136677 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel thorn distillate (n = 49)
Number of subjects: 93
Study 20136677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 93
Study 18709235 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (12.5mg Fe/day)
Number of subjects: 297
Study 18709235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (25mg Fe/week)
Number of subjects: 297
Study 18709235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 297
Study 15957672 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment for female alcoholics
Number of subjects: 109
Study 15957672 — intervention group
Group type: COMPARATOR
Intervention: Couple treatment for female alcoholics
Number of subjects: 109
Study 12575967 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EVBT) with iridium 192; 14 Gy at a depth of the radius of the vessel +2 mm
Number of subjects: 204
Study 12575967 — intervention group
Group type: COMPARATOR
Intervention: None (control group with stents without EVBT)
Number of subjects: 204
Study 12575967 — intervention group
Group type: COMPARATOR
Intervention: None (control group undergoing EVBT after simple balloon angioplasty)
Number of subjects: 204
Study 10769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate and hydroxyzine (CH-H)
Number of subjects: 300
Study 10769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate, meperidine, and hydroxyzine (CH-D-H)
Number of subjects: 300
Study 10769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (M)
Number of subjects: 300
Study 9277245 — intervention group
Group type: EXPERIMENTAL
Intervention: Logbook intervention for trial patients
Number of subjects: 71
Study 9277245 — intervention group
Group type: EXPERIMENTAL
Intervention: Logbook intervention for care-professionals
Number of subjects: 71
Study 9277245 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no logbook)
Number of subjects: 71
Study 8394861 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate (Sbv) at 20 mg/kg/day for 30 days (group S)
Number of subjects: 200
Study 8394861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (Sbv) at 20 mg/kg/day plus aminosidine at 15 mg/kg/day for 17 days (group AS)
Number of subjects: 200
Study 3089361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin suspension or pastilles (new formulation)
Number of subjects: 50
Study 3089361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin pastilles
Number of subjects: 50
Study 3089361 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment of dentures
Number of subjects: 50
Study 31863911 — intervention group
Group type: EXPERIMENTAL
Intervention: Male dog allergen extract
Number of subjects: 22
Study 31863911 — intervention group
Group type: EXPERIMENTAL
Intervention: Female dog allergen extract
Number of subjects: 22
Study 31863911 — intervention group
Group type: COMPARATOR
Intervention: Mix of dog components
Number of subjects: 22
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding maintenance for at least 6 months
Number of subjects: 228